OBJECTIVES: To describe the CT changes in patients with restrictive allograft syndrome (RAS) after lung transplantation, before and after clinical diagnosis. METHODS: This retrospective study included 22 patients with clinical diagnosis of RAS. Diagnosis was based on a combination of forced expiratory volume (FEV1) decline (≥20 %) and total lung capacity (TLC) decline (≥10 %). All available CT scans after transplantation were analyzed for the appearance and evolution of lung abnormalities. RESULTS: In 14 patients, non-regressing nodules and reticulations predominantly affecting the upper lobes developed an average of 13.9 months prior to the diagnosis of RAS. Median graft survival after onset of non-regressing abnormalities was 33.5 months, with most patients in follow-up (9/14). In eight patients, a sudden appearance of diffuse consolidations mainly affecting both upper and lower lobes was seen an average of 2.8 months prior to the diagnosis of RAS. Median graft survival was 6.4 months after first onset of non-regressing abnormalities, with graft loss in most patients (6/8). CONCLUSIONS: RAS has been previously described as a homogenous group. However, our study shows two different groups of RAS-patients: one with slow progression and one with fast progression. The two groups show different onset and progression patterns of CT abnormalities. KEY POINTS: • RAS is the newest discovered form of chronic lung allograft dysfunction (CLAD). • RAS is not a homogenous group, as survival varies greatly between patients. • In this study, we see two different CT onset and progression patterns. • These two different CT patterns also correlate with a different survival rate.
OBJECTIVES: To describe the CT changes in patients with restrictive allograft syndrome (RAS) after lung transplantation, before and after clinical diagnosis. METHODS: This retrospective study included 22 patients with clinical diagnosis of RAS. Diagnosis was based on a combination of forced expiratory volume (FEV1) decline (≥20 %) and total lung capacity (TLC) decline (≥10 %). All available CT scans after transplantation were analyzed for the appearance and evolution of lung abnormalities. RESULTS: In 14 patients, non-regressing nodules and reticulations predominantly affecting the upper lobes developed an average of 13.9 months prior to the diagnosis of RAS. Median graft survival after onset of non-regressing abnormalities was 33.5 months, with most patients in follow-up (9/14). In eight patients, a sudden appearance of diffuse consolidations mainly affecting both upper and lower lobes was seen an average of 2.8 months prior to the diagnosis of RAS. Median graft survival was 6.4 months after first onset of non-regressing abnormalities, with graft loss in most patients (6/8). CONCLUSIONS: RAS has been previously described as a homogenous group. However, our study shows two different groups of RAS-patients: one with slow progression and one with fast progression. The two groups show different onset and progression patterns of CT abnormalities. KEY POINTS: • RAS is the newest discovered form of chronic lung allograft dysfunction (CLAD). • RAS is not a homogenous group, as survival varies greatly between patients. • In this study, we see two different CT onset and progression patterns. • These two different CT patterns also correlate with a different survival rate.
Authors: Geert M Verleden; Robin Vos; Bart Vanaudenaerde; Lieven Dupont; Jonas Yserbyt; Dirk Van Raemdonck; Stijn Verleden Journal: Transpl Int Date: 2015-04-23 Impact factor: 3.782
Authors: Elbert P Trulock; Leah B Edwards; David O Taylor; Mark M Boucek; Berkeley M Keck; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2005-08 Impact factor: 10.247
Authors: Roger D Yusen; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Anne I Dipchand; Fabienne Dobbels; Samuel B Goldfarb; Bronwyn J Levvey; Lars H Lund; Bruno Meiser; Josef Stehlik Journal: J Heart Lung Transplant Date: 2014-08-14 Impact factor: 10.247
Authors: Smita Sakha Pakhale; Denis Hadjiliadis; David N Howell; Scott M Palmer; Carlos Gutierrez; Thomas K Waddell; Cecilia Chaparro; R Duane Davis; Shaf Keshavjee; Michael A Hutcheon; Lianne G Singer Journal: J Heart Lung Transplant Date: 2005-09 Impact factor: 10.247
Authors: S E Verleden; J L Todd; M Sato; S M Palmer; T Martinu; E N Pavlisko; R Vos; A Neyrinck; D Van Raemdonck; T Saito; H Oishi; S Keshavjee; M Greer; G Warnecke; J Gottlieb; A Haverich Journal: Am J Transplant Date: 2015-04-30 Impact factor: 8.086
Authors: James P Woodrow; Oksana A Shlobin; Scott D Barnett; Nelson Burton; Steven D Nathan Journal: J Heart Lung Transplant Date: 2010-06-26 Impact factor: 10.247
Authors: Stijn E Verleden; David Ruttens; Elly Vandermeulen; Hannelore Bellon; Dirk E Van Raemdonck; Lieven J Dupont; Bart M Vanaudenaerde; Geert Verleden; Robin Vos Journal: J Heart Lung Transplant Date: 2014-11-11 Impact factor: 10.247
Authors: R Vos; S E Verleden; D Ruttens; E Vandermeulen; J Yserbyt; L J Dupont; D E Van Raemdonck; N De Raedt; O Gheysens; P A De Jong; G M Verleden; B M Vanaudenaerde Journal: Am J Transplant Date: 2013-09-18 Impact factor: 8.086
Authors: Geert M Verleden; Ganesh Raghu; Keith C Meyer; Allan R Glanville; Paul Corris Journal: J Heart Lung Transplant Date: 2013-10-24 Impact factor: 10.247